Overview

Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy

Status:
Completed
Trial end date:
2021-08-23
Target enrollment:
Participant gender:
Summary
This is a proof of concept (PoC) trial to evaluate the safety, tolerability and renal effect of APX-115 in subjects with Type 2 diabetes and nephropathy.
Phase:
Phase 2
Details
Lead Sponsor:
Aptabio Therapeutics, Inc.